LIFETECH SCIENTIFIC CORPORATION LifeTech Scientific Corporation Stock
Equities
1302
KYG548721177
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.69 HKD | +0.60% |
|
-2.31% | -28.09% |
| Sales 2024 * | 1.47B 204M 1.59B | Sales 2025 * | 1.77B 245M 1.92B | Capitalization | 7.25B 1B 7.82B |
|---|---|---|---|---|---|
| Net income 2024 * | 328M 45.3M 354M | Net income 2025 * | 399M 55.1M 431M | EV / Sales 2024 * | 4.92 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.09 x |
| P/E ratio 2024 * |
22.4
x | P/E ratio 2025 * |
17.4
x | Employees | 1,448 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.41% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.60% | ||
| 1 week | -2.31% | ||
| 1 month | -1.74% | ||
| 3 months | -15.08% | ||
| 6 months | -29.58% | ||
| Current year | -28.09% |
1 week
1.62
1.77
1 month
1.622.00
Current year
1.562.39
1 year
1.563.02
3 years
1.565.86
5 years
1.135.98
10 years
0.725.98
| Managers | Title | Age | Since |
|---|---|---|---|
Yue Hui Xie
CEO | Chief Executive Officer | 54 | 06-08-16 |
Jian Xiong Liu
DFI | Director of Finance/CFO | 53 | 10-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jian Xiong Liu
DFI | Director of Finance/CFO | 53 | 10-08-31 |
Feng Jiang
BRD | Director/Board Member | 61 | 14-03-31 |
Yue Hui Xie
CEO | Chief Executive Officer | 54 | 06-08-16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.16% | 2 M€ | -14.14% | ||
| 0.02% | 112 M€ | +4.61% | - | |
| 0.02% | 4 M€ | -4.41% | - | |
| 0.00% | 45 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1.69 | +0.60% | 20,928,000 |
| 24-05-30 | 1.68 | -0.59% | 6,414,000 |
| 24-05-29 | 1.69 | -.--% | 15,036,000 |
| 24-05-28 | 1.69 | -0.59% | 8,296,000 |
| 24-05-27 | 1.7 | -1.73% | 6,372,000 |
Delayed Quote Hong Kong S.E., May 31, 2024 at 04:08 am EDT
More quotes
LifeTech Scientific Corporation is an investment holding company principally engaged in the manufacturing and marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The Company operates through three business segments. The Congenital Heart Diseases Business segment is engaged in the research and development, manufacture and trading of devices related to congenital and structural heart diseases. The Peripheral Vascular Diseases Business segment is engaged in the research and development, manufacture and trading of devices related to peripheral vascular diseases. The Surgical Vascular Repair Business segment is engaged in the research and development, manufacture and trading of devices related to surgical vascular repair.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.565
CNY
Average target price
2.436
CNY
Spread / Average Target
+55.65%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.09% | 1B | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.61B |
- Stock Market
- Equities
- 1302 Stock
